According to Zacks, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. “
Several other research analysts have also issued reports on the stock. Wedbush reissued a “buy” rating and set a $6.00 target price on shares of Zafgen in a research note on Thursday, May 30th. Cowen reissued a “hold” rating on shares of Zafgen in a research note on Thursday, May 30th. Piper Jaffray Companies cut their target price on shares of Zafgen from $6.00 to $5.00 and set a “hold” rating on the stock in a research note on Thursday, May 30th. ValuEngine lowered shares of Zafgen from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Roth Capital began coverage on shares of Zafgen in a research note on Friday, April 26th. They set a “buy” rating and a $8.00 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company’s stock. Zafgen presently has an average rating of “Hold” and a consensus target price of $7.00.
Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.05. On average, equities research analysts anticipate that Zafgen will post -1.4 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its position in shares of Zafgen by 66.7% in the fourth quarter. Rhumbline Advisers now owns 39,391 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 15,758 shares during the period. Prudential Financial Inc. purchased a new stake in shares of Zafgen in the fourth quarter valued at $65,000. BlackRock Inc. grew its position in shares of Zafgen by 22.4% in the fourth quarter. BlackRock Inc. now owns 2,596,716 shares of the biopharmaceutical company’s stock valued at $12,853,000 after purchasing an additional 474,896 shares during the period. Bank of New York Mellon Corp grew its position in Zafgen by 3.0% during the fourth quarter. Bank of New York Mellon Corp now owns 161,552 shares of the biopharmaceutical company’s stock valued at $800,000 after acquiring an additional 4,699 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Zafgen during the fourth quarter valued at about $341,000. 84.26% of the stock is currently owned by institutional investors and hedge funds.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
Read More: Municipal Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.